Medical News Observer

Key Points:

• The cholangiocarcinoma-on-chip integrates primary cholangiocarcinoma cells, cancer-associated fibroblasts, endothelial cells, and T cells in a three-channel chip architecture, creating a detailed replica of the tumor environment.
• The model successfully maintains the original cellular phenotype and function, mimicking in vivo conditions, including hydrogel stiffness and extracellular matrix deposition, with added insights into T-cell interactions.
• This model offers a promising platform for tailored drug testing and personalized medicine research.

Overview

Cholangiocarcinoma is a rare and aggressive biliary tract cancer and is often diagnosed at an advanced stage, limiting treatment options. Researchers have created a sophisticated 3D model of cholangiocarcinoma using “organ-on-chip” technology to revolutionize cholangiocarcinoma research and enhance precision medicine.

Development of Cholangiocarcinoma-on-chip 

This microfluidic device accurately replicates the complex tumor microenvironment by incorporating primary cholangiocarcinoma cells, cancer-associated fibroblasts (CAFs), endothelial cells, and T cells from cholangiocarcinoma specimens from patients. Researchers used a three-channel chip architecture in this platform. This architecture allows for the co-culture of cholangiocarcinoma and cancer-associated fibroblasts flanked by endothelial cells to form a tubular structure. Overall, this micro-sized prototype intricately mimics the cancer’s microenvironment, featuring microchannels that accurately represent the disease. 

Researchers also noted that the cholangiocarcinoma-on-chip model underwent extensive characterization, demonstrating its ability to maintain the original cellular phenotype and function, increase hydrogel stiffness, and enhance extracellular matrix deposition, thus closely resembling in vivo cholangiocarcinoma characteristics. Importantly, including T cells from patient specimens enabled the assessment of immune cell interactions, with variations in T cell migration reflecting patient-specific tumor characteristics. 

Implications and Future

This “cholangiocarcinoma-on-chip” technology, personalized for each patient, is crafted from the patient’s cancer cells. It offers a new laboratory model resembling patient conditions and is a potential platform for personalized drug testing. The researchers plan to optimize this model further for research and drug testing, including introducing elements like macrophages and micro-pumps to mimic blood flow and tumor progression better.

Italian Foundation for Cancer Research (AIRC) funded this research.

References

Polidoro, Michela Anna, Erika Ferrari, Cristiana Soldani, Barbara Franceschini, Giuseppe Saladino, Arianna Rosina, Andrea Mainardi, et al. 2024. “Cholangiocarcinoma-on-a-Chip: A Human 3D Platform for Personalised Medicine.” JHEP Reports 6 (1). https://doi.org/10.1016/j.jhepr.2023.100910.